1. Harrington C, Gregorian R, Gemmen E, Hughes C, Golden K, Robinson G et al. Access and utilization of new antidepressant and antipsychotic medications. Lewin Group: Falls Church, VA, 2000 (Accessed 17 August 2006, at
http://aspe.hhs.gov/search/health/reports/Psychmedaccess/index.htm#TOC
).
2. Haro JM, Salvador-Carulla L . The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 2006; 20: 293–301.
3. Newcomer JW . Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68 (Suppl 1): 20–27.
4. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity. Diabetes Care 2004; 27: 596–601.
5. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65 (Suppl 7): 4–18.